HOME HELP FEEDBACK SUBSCRIPTIONS ALL ISSUES SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tariot, P. N. Articles by Frambes, N. Search for Related Content PubMed PubMed Citation Articles by Tariot, P. N. Articles by Frambes, N.

Short-Term Administration of Selegiline for Mild-to-Moderate Dementia of the Alzheimer's Type

Received November 5, 1996; accepted May 26, 1997. From the Program in Neurobehavioral Therapeutics, Department of Psychiatry, University of Rochester School of Medicine, Rochester, New York. Address correspondence to Dr. Tariot, Program in Neurobehavioral Therapeutics, Monroe Community Hospital, 435 East Henrietta Road, Rochester, NY 14620.

As a follow-up to an earlier study showing short-term benefit in inpatients with more severe dementia, the authors studied the short-term cognitive, functional, and behavioral effects of selegiline in outpatients with mild-to-moderate dementia of the Alzheimer type (DAT) by means of a double-blind, randomized, crossover study of placebo vs. selegiline. Fifty outpatients with mild-to-moderate DAT and no behavioral disturbances were given selegiline in two 8-week treatment periods separated by a 4-week washout. Outcome was assessed with standardized measures of dementia severity, daily functioning, behavior, and cognition. There was no drug–placebo difference in any outcome measure. Selegiline did not show short-term benefit in this study, contrary to the earlier study, perhaps because the patients were studied less intensively and/or lacked behavioral problems that could show response, although the medication was well tolerated.

Key Words: Selegiline • dementia • Alzheimer's disease

This article has been cited by other articles:

				S. Yasar, Z. Justinova, S.-H. Lee, R. Stefanski, S. R. Goldberg, and G. Tanda Metabolic Transformation Plays a Primary Role in the Psychostimulant-Like Discriminative-Stimulus Effects of Selegiline [(R)-(-)-Deprenyl] J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 387 - 394. [Abstract] [Full Text] [PDF]